Shelley Force Aldred, Ph.D.
VP for Preclinical Development, TeneoBio, Inc.
Shelley Force Aldred has spent the past 3 years serving as VP for Preclinical Development at
TeneoBio, a multi-specific therapeutic antibody company. Dr. Force Aldred was part of the formation of TeneoBio and led the preclinical efforts creating a CD3xBCMA bispecific antibody, from product concept to IND-ready package. Her group developed a high-throughput workflow for evaluating thousands of lead antibodies in complex cell-based models.
Dr. Force Aldred was formerly director of worldwide R&D for Active Motif following the acquisition of SwitchGear Genomics in 2013. In 2006, she co-founded SwitchGear Genomics, a venture-backed functional genomics platform company, and she served as its President and Board Member. Prior to founding SwitchGear Genomics, Dr. Force Aldred was a Scientific Director on Stanford’s ENCODE Project and received her Ph.D. in Genetics from Stanford University. She is an inventor on over 15 patents and an author on over 20 peer-reviewed scientific publications.